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SUMMARY 
 
The in vivo formation of fibrillar proteinaceous deposits called amyloid is associated 
with more than 40 serious human diseases, collectively referred to as protein 
deposition diseases. In many cases the amyloid deposits are extracellular and are 
found associated with newly identified abundant extracellular chaperones (ECs). 
Evidence is presented suggesting an important regulatory role for ECs in amyloid 
formation and disposal in the body. A model is presented which proposes that, under 
normal conditions, ECs stabilize extracellular misfolded proteins by binding to them, 
and then guide them to specific cell receptors for uptake and subsequent degradation. 
Thus ECs and their receptors may be critical parts of a quality control system to 
protect the body against dangerously hydrophobic proteins/peptides. However, it also 
appears possible that in the presence of a high molar excess of misfolded protein, such 
as might occur during disease, the limited amounts of ECs available may actually 
exacebate pathology. Further advances in understanding of the mechanisms that 
control extracellular protein folding are likely to identify new strategies for effective 
disease therapies.  
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1.0 INTRODUCTION 
 
The term "molecular chaperone" was first developed in the late 1970's when 
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referring to the ability of nucleoplasmin to inhibit inappropriate interactions between 
histones and DNA.1 The meaning of this term is continuing to evolve but two key 
properties of molecular chaperones are (i) selective binding to non-native protein 
conformations to form stable complexes, and (ii) inhibition of the irreversible 
aggregation of non-native protein conformations.2 Many molecular chaperones 
maintain other proteins in "folding-competent" conformations, which are returned to 
the native conformation by the involvement of other refolding chaperones. Previous 
studies have overwhelmingly focussed on intracellular molecular chaperones and their 
roles in protein folding within the cell. The discoveries that a range of serious human 
diseases are related to protein aggregation phenomena, and that molecular chaperones 
affect these processes, has led to a recent explosion of research in this area. The 
pathology of more than 40 human degenerative diseases is associated with the 
deposition of fibrillar proteinaceous aggregates called amyloid. Collectively referred 
to as protein deposition diseases, these include various sporadic (e.g. Alzheimer’s 
(AD) and Parkinson's (PD) diseases), familial, and transmissible degenerative 
disorders (e.g. spongiform encephalopathies such as Creutzfeldt-Jakob disease (CJD)), 
many of which affect, amongst other tissues and organs, the brain and the central 
nervous system (CNS). In many cases, molecular chaperones have been found 
physically associated with amyloid deposits, although the reason for this association 
remains to be established.  
 
It has only recently become apparent that extracellular counterparts to the intracellular 
molecular chaperones exist. The role of these abundant extracellular chaperones (ECs) 
in the formation of amyloid deposits in vivo is emerging as an exciting field. In this 
review, we briefly introduce the molecular basis of amyloid formation, examine the 
available evidence that ECs influence this process, and discuss the potential roles of 
ECs in amyloid formation and disposal in vivo. 
 
2.0 AMYLOIDS  
 
2.1 Amyloid formation  
The hallmark of a wide range of debilitating and incurable human pathologies is the 
abnormal presence of extracellular deposits in a variety of organs and tissues, 
including the brain and CNS (e.g. AD, CJD), peripheral organs such as the heart, liver, 
and spleen (e.g. systemic amyloidoses), and skeletal tissues and joints (e.g. 
haemodialysis-related amyloidosis). There are many excellent reviews of the 
molecular events underlying amyloid formation (e.g. 3); only a very brief overview is 
provided here.  
 
Amyloid fibrils arise when a specific protein or protein fragment converts from an 
otherwise soluble form into insoluble filamentous aggregates. It appears that the 
aggregation behaviours of various amyloid-forming peptides and proteins are 
strikingly similar. The kinetics of amyloid formation (as measured by Thioflavin T 
fluorescence or light scattering) is generally characterized by an initial ‘lag’ or 
nucleation phase, followed by a rapid exponential ‘growth’ or polymerization phase,4 
and lastly, by a plateau phase in which no further polymerization occurs (Fig. 1). The 
lag (or nucleation) phase is defined as the time required for the formation of the 
soluble (prefibrillar) oligomers or nuclei. This phase begins with the destabilization 
and partial unfolding of the native protein, leading to the formation of an ensemble of 
intermediately folded species. Structural perturbation leading to protein unfolding can 
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be achieved by exposing the native protein to one or more chaotropic conditions, 
including elevated temperature, low pH, oxidative stress, molecular crowding, and 
protease-mediated degradation.5 A subset of proteins within this ensemble will 
undergo non-ordered aggregation to form nuclei. After nucleation and immediately 
preceding the polymerization phase, the nuclei transform into an ensemble of various 
assemblies called protofibrils that exhibit increased levels of complexity. During the 
polymerization phase, these protofibrils rapidly grow to form well-ordered 
protofilaments which laterally associate to give rise to mature amyloid fibrils.6 
 
Typically, amyloid fibrils exist as long, unbranched, but often twisted structures that 
are 6-12 nanometres in diameter, bearing a characteristic ‘cross-’ X-ray fibre 
diffraction pattern.7 Each fibril is usually comprised, within its core structure, of two 
to six ‘protofilaments’ that wind around each other to form supercoiled rope-like 
structures. Protofilaments are believed to be principally stabilized by intra- and 
intermolecular interactions (e.g. hydrogen bonds) and are composed of -sheets 
whose strands lie perpendicular to the long axis of the fibril.8; 9  
 
2.2 Causes of amyloid pathology 
Numerous theories have been advanced to account for the pathology of amyloid 
diseases, many focusing on the toxic nature of amyloids and how this relates to 
neuronal loss in the brain (reviewed in Stefani and Dobson10). In some cases, disease 
pathology might simply be attributed to the shear bulk of deposited material present in 
the affected organs and tissues, which can cause physical disruption to the cellular 
architecture, subsequently leading to organ dysfunction (e.g. some of the systemic 
amyloidoses). However, an alternative widely accepted theory suggests that soluble, 
toxic protein aggregates are the primary cause of pathogenesis in disorders such as 
AD. An increasing quantity of data suggests that pre-fibrillar structures (e.g. 
oligomers and protofibrils) are toxic, rather than the mature fibrils into which they 
develop.11 The demonstration that these species are, in addition to being highly 
cytotoxic, readily diffusible throughout the brain may explain why neuronal loss is 
commonly observed at sites distant from those of the amyloid deposits. By proposing 
that the primary toxic species are the early aggregates, this theory also provides a 
plausible explanation for the lack of correlation between the extent of deposition of 
mature fibrils in the form of amyloid plaques in the diseased brain and the severity of 
clinical symptoms.12   
 
3.0 EXTRACELLULAR CHAPERONES 
There is evidence to suggest that there are control mechanisms for protein folding in 
extracellular spaces. For example, although cerebrospinal fluid (CSF) is regularly 
released into the venous system through the arachnoid villi, the half lives of proteins 
in the CSF differ from protein to protein, and even differ between various proteolytic 
fragments of the same original protein,13 suggesting a selective mechanism of 
removal. In the event of a large-scale presentation of extracellular non-native 
protein(s), such as might occur during amyloid disease, only physically abundant 
extracellular chaperone(s) could reasonably be expected to provide an effective line of 
defense. “Normally intracellular” chaperones (e.g. Hsp70) are present extracellularly 
at very low (ng/ml) levels, thus, their capacity would be quickly exceeded. It is 
therefore likely that bulk processing of non-native proteins is dealt with by much 
more abundant proteins with chaperone properties, herafter referred to as extracellular 
chaperones (ECs), which have only recently been identified. 
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Four secreted glycoproteins, clusterin,14 haptoglobin,15 2-macroglobulin (French et 
al., unpublished work) and serum amyloid P component (SAP),16 have been shown to 
exhibit chaperone properties in vitro. The first three of these proteins share functional 
characteristics with the small heat shock proteins in that they are able to efficiently 
stabilize misfolded proteins to prevent them aggregating but are not capable of 
independently refolding proteins.  
 
3.1 Clusterin 
Clusterin is secreted from many different cell types and is found in human plasma, 
CSF and seminal fluid at concentrations of approximately 100, 2, and 1000 g/ml,17; 
18; 19 respectively. The expression of clusterin is increased in a wide variety of models 
of stress and disease, including withdrawal of growth factors and exposure to noxious 
agents.20 The transcriptional regulator heat shock factor 1 (HSF1) binds to a highly 
conserved 14 bp element in the clusterin promoter21 and activates expression of both 
clusterin and heat shock proteins (which protect cells from stresses).21 Clusterin is 
encoded by a single gene and the translated product is internally cleaved to produce 
its  and subunits, and glycosylated, prior to secretion from the cell. The exclusively 
N-linked glycosylation is variable in nature and extent, ranging from 17-27% (by 
weight).22 In aqueous solution at physiological pH, clusterin exists in a range of 
oligomeric forms; mildly acidic pH favours partial dissociation of oligomers into 
individual - heterodimers.23 Current insights into clusterin structure are largely 
reliant upon predictions based on sequence analyses, which suggest that the protein 
has significant contiguous regions of disordered conformation that separate other 
regions of well-defined secondary structure, such as amphipathic -helical regions 
and coiled-coil -helices.24; 25 The high level of disorder, variable glycosylation and 
tendency to form oligomers have so far limited attempts to structurally characterise 
clusterin.  
 
Recent studies have demonstrated that clusterin has chaperone activity with a potent 
ability to influence the amorphous and fibrillar aggregation of many different proteins. 
Clusterin inhibits stress-induced protein aggregation by ATP-independent binding to 
exposed regions of hydrophobicity on non-native proteins to form soluble, high 
molecular mass complexes.26; 27; 28 Immunoaffinity depletion of clusterin from human 
plasma renders proteins in this fluid more susceptible to aggregation and 
precipitation.29 Clusterin lacks the ability to independently refold heat-stressed, non-
native enzymes but, like the small heat shock proteins, is able to preserve heat-
inactivated enzymes in a state competent for subsequent ATP-dependent refolding by 
Hsc70.27 However, because there is no currently known abundant refolding-
competent EC, the physiological significance of this remains uncertain. During 
amorphous aggregation of proteins, clusterin appears to interact with slowly 
aggregating species on the off-folding pathway. Interestingly, where tested, clusterin 
has been found associated with all amyloid deposits.28 
 
By complexing with misfolded extracellular proteins, ECs like clusterin may mediate 
their cellular uptake and degradation.30 Clusterin has long been known to interact with 
the cell surface receptor megalin (LRP2) and to complex with A to mediate its 
uptake by megalin and subsequent degradation.31 It also interacts with other members 
of the low density lipoprotein (LDL) receptor family - it binds to chicken LR8 and an 
LDLR-related protein,32 and uptake of clusterin-leptin complexes by apoER2 and 
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VLDLR  has been proposed to facilitate leptin clearance.33 Furthermore, clusterin and 
LRP1/megalin have been implicated in the clearance of cellular debris by fibroblasts 
and epithelial cells.34  
 
3.2 Haptoglobin 
Haptoglobin (Hp) is a secreted acidic glycoprotein produced mainly in the liver and 
found in most body fluids of humans and other mammals. Normally, it is present in 
human plasma at 300-2000 g/ml35 and CSF at 0.5-2 g/ml.36 However, the levels of 
Hp in human plasma are increased up to 8-fold during various physiological stresses 
(e.g. inflammation), leading to it being designated as an "acute phase protein".35; 37 Hp 
is encoded by a single gene; uniquely, in humans, there are two principal alleles (Hp1 
and Hp2), which results in individual humans expressing one of three major Hp 
phenotypes (Hp 1-1, Hp 2-1, Hp 2-2). In all cases, Hp can be represented as a 
multimer of an αβ subunit. In its simplest form (Hp 1-1), Hp consists of a disulfide-
linked (α1)2β2 structure (~100 kDa). However, in Hp 2-1 and Hp 2-2, an additional 
cysteine residue in the α2 chain allows the formation of a complex series of various 
sized disulfide-linked αβ polymers (~100 to ~500 kDa).  
 
Hp binds with extremely high affinity to hemoglobin (Hb) (KD ~ 10
-15 M)35. 
Formation of the Hp-Hb complex inhibits Hb-mediated generation of  lipid peroxides 
and hydroxyl radical, which is thought to occur in areas of inflammation.37 Hp has 
also been implicated in immune regulation38 and shown to inhibit cathepsin B 
activity.39 Binding of Hp to human neutrophils has been reported to inhibit respiratory 
burst activity.40 In addition, neutrophils have been shown to take up exogenous Hp 
and store it within cytoplasmic granules - they subsequently secrete it into the local 
extracellular environment in response to a variety of pro-inflammatory stimuli (e.g. 
yeast, TNF, or the chemotactic peptide fMLP41; 42). Thus, the available evidence 
indicates that Hp is likely to play an important role in suppressing inflammatory 
responses.  

Human Hp specifically inhibits the precipitation of a wide variety of proteins induced 
by a range of stresses.15; 43 All three human Hp phenotypes exert this chaperone action, 
although at equivalent mass concentrations, at least for one substrate protein tested, 
Hp1-1 was the most efficient. Like clusterin, Hp forms stable, soluble high molecular 
mass complexes with misfolded proteins. Also like clusterin, Hp lacks ATPase 
activity and has no independent ability to refold misfolded proteins. The possibility 
that Hp holds misfolded proteins in a state competent for refolding by other 
chaperones is currently untested. Immunoaffinity depletion of Hp from human serum 
significantly increased the amount of protein that precipitated in response to 
stresses.15 Thus, Hp has the ability to protect many different proteins from stress-
induced amorphous precipitation and its effects in whole human serum suggest that 
this activity is likely to be relevant in vivo. Currently, there are no published studies of 
the effects of Hp on amyloid formation, although Hp is found associated with A 
amyloid deposits in vivo.44 
 
When complexed to Hb, Hp is known to bind to the CD163 cell surface receptor.45 
Other receptors to which Hp binds are the CD11b/CD18 integrin (Mac-1/CR3), which 
also binds denatured proteins and the iC3b fragment of complement,46 and the CD22 
B lymphocyte receptor. Unidentified specific Hp binding sites have also been 
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reported to occur on neutrophils40 and mast cells.47 Thus, it appears feasible that Hp 
might interact with one or more of these receptors to mediate the clearance and 
degradation of misfolded extracellular proteins. 
 

2-Macroglobulin (2M) 

2-Macroglobulin (2M) is a major human blood glycoprotein, comprised of ~10% 
carbohydrate by mass. It is assembled from four identical 180 kDa subunits into a 720 
kDa tetramer; the 180 kDa subunits are disulphide bonded to form dimers, which non-
covalently interact to yield the final tetrameric quaternary structure.48 2M is present 
in human plasma and CSF at 1500-200049 and 1-3.6 g/ml,50 respectively. It has a 
well-known ability to inhibit a broad spectrum of proteases, which it accomplishes 
using a unique trapping method. When exposed to a protease, 2M undergoes limited 
proteolysis at its bait region leading to a large conformational change, physically 
trapping the protease within a steric “cage”.49 The trapped protease forms a covalent 
linkage with 2M by reacting with an intramolecular thiol ester bond to yield a 
conformationally altered form known as “activated” or “fast” 2M (2M*), which 
exposes a receptor recognition site for low density lipoprotein receptor related protein 
(LRP).49 By directly interacting with the thiol ester bond, small nucleophiles such as 
methylamine can also activate 2M.51  
 
Aside from its interactions with proteases, 2M binds to A peptide, prion protein and 
2-microglobulin, which are associated with Alzheimer’s disease,52spongiform 
encephalopathies53 and dialysis related amyloidosis,54 respectively, to cytokines and 
growth factors,55 and to a range of hydrophobic molecules including endotoxin, 
phenyl-Sepharose, and liposomes.56 The binding to hydrophobic molecules does not 
inhibit the trapping of proteases and is not known to be associated with any 
conformational changes.56 In addition, 2M is found associated with amyloid deposits 
in AD and spongiform encephalopathies.53; 57 Previous work has indicated that 2M-
polypeptide complexes are immunogenic.58; 59 2M bound peptides are internalised by 
LRP and fragments of the peptide are subsequently re-presented on the cell surface. 
This response is identical to the one elicited by peptides chaperoned by intracellular 
heat shock proteins.60 A further hint that 2M might have chaperone properties came 
from the observation that it inhibits the aggregation of A and protects cells from A 
toxicity.61 It was recently shown that 2M has a promiscuous ATP-independent 
chaperone action similar to that of both clusterin and haptoglobin. It forms stable 
complexes with misfolded proteins to inhibit their stress-induced aggregation and 
precipitation but is unable to independently effect their refolding (French et al., 
unpublished work). 2M is the first known mammalian protein with both protease 
inhibitor and chaperone-like activities. 
 
 
3.4 Serum amyloid P component 
 
SAP is a member of the pentraxin family of proteins which are characterised by five 
identical subunits noncovalently associated to form a disc-like structure. The SAP 
pentamer consists of five 25 kDa subunits rich in anti-parallel β -strands, each 
containing 204 amino acids, an invariant N-linked biantennary oligosaccharide 
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(constituting more than 8% of the mass of the molecule62), and a single intra-chain 
disulfide bond.63 It has been proposed that SAP circulates as a decamer with two 
pentameric discs noncovalently bound face to face.63; 64 Other reports claim that the 
decameric form of SAP is obtained only upon purification.65; 66 SAP is synthesised 
and catabolized in the liver, and is present in human plasma and CSF at 
concentrations of ~ 40 g/mL67 and 8.5 g/ml,68 respectively. Whereas SAP is an 
acute-phase protein in mice,69 in humans its plasma concentration is not significantly 
elevated during acute inflammation.70 Each subunit monomer has two Ca2+-binding 
sites and shows Ca2+-dependent binding to many different ligands, including certain 
oligosaccharides, glycosaminoglycans,71 fibronectin,72 C-reactive protein,73 
aggregated IgG,74 C1q,75 complement C4-binding protein,75 DNA,76 chromatin,77 
histones,78 and phosphoethanolamine-containing compounds such as 
phosphatidylethanolamine.63 Interaction with these ligands localises SAP to elastic 
microfibrils,79 glomerular and alveolar basement membrane, arterioles, bronchioles, 
sarcolemma of cardiac and smooth muscle,80 and all forms of amyloid.81  
 
Previous studies of the chaperone properties of SAP are insufficient in number and 
depth to allow unequivocal classification of SAP, together with clusterin, haptoglobin 
and 2M as a genuine EC. However, one study showed that when added to a refolding 
buffer containing denatured lactate dehydrogenase (LDH), SAP markedly enhanced 
the yield of active LDH; the reaction was Ca2+-independent and supra-stoichometric, 
a ratio of SAP pentamer to LDH substrate of 10:1 was needed to recover 25% of 
enzyme reactivity.16 This suggests that SAP is an inefficient refolding-competent 
chaperone. It is important to note that this in vitro activity was demonstrated in the 
absence of ATP and any "helper" chaperones. Clearly, further studies of the 
chaperone properties of SAP and how they might relate to known ECs will be 
valuable. Of particular interest in the current context, SAP has been found present in 
all amyloid deposits examined.82; 83; 84; 85 The interaction between SAP and amyloid 
fibrils is highly specific, and the abundance of SAP in amyloid fibrils relative to its 
trace concentration in plasma is extraordinary.86 SAP has a protease-resistant -
pleated sheet structure that in the presence of Ca2+ is resistant to proteolysis.87 
Furthermore, it has been shown that SAP inhibits the degradation of several types of 
amyloid fibrils by proteases. Tennent et al. 88 suggested that SAP protects amyloid 
from proteolytic degradation in vivo by binding to fibrils and masking fibrillar 
conformation. 
 
 
4.0 THE EFFECTS OF EXTRACELLULAR CHAPERONES ON AMYLOID 
FORMATION AND TOXICITY 
 
4.1 Effects of ECs on amyloid formation in vitro 
In vivo amyloid formation and deposition is an extraordinarily complex process that 
can occur over much of the lifetime of an individual, thus making it difficult to 
monitor and study over a reasonable timescale. Although this complexity prevents the 
amyloid-forming process from being fully reproduced in a test tube, by examining 
individual steps in the process in vitro, it is still possible to gain insight into many 
facets of in vivo amyloid formation and deposition. In vitro, conditions can be 
manipulated such that fibril formation can be assessed in a manageable timeframe. 
Much of the current knowledge regarding the effects of ECs on amyloid formation 
has been obtained from in vitro studies that utilise such strategies. Whilst many 
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studies have highlighted the ability of ECs to suppress amorphous aggregation, their 
effects on amyloid formation are, apart from clusterin, less well-documented. In 
1994,89 it was shown that the formation of A fibrils could be inhibited by sub-
stoichiometric levels of clusterin, a finding which has since been confirmed by other 
independent studies.90; 91 Since then, clusterin has been shown to potently inhibit the 
formation of fibrils derived from a broad range of other unrelated ‘substrates’, 
including prion protein Pr106-126,
92 Apo C-II,93 chicken egg white lysozyme, calcitonin, 
-casein, -synuclein, 2-microglobulin, PI3-SH3, A, a model peptide CCw,28 and 
the naturally occurring amyloidogenic variant of lysozyme, I56T.94 Similar inhibitory 
capabilities have also been documented for 2M. Like clusterin, sub-stoichiometric 
levels of 2M (a 1:8 molar ratio of 2M:substrate) were enough to completely inhibit 
the formation of fibrillar A aggregates.90 Finally, it was shown that in vitro a 1:5 
molar ratio of SAP to target protein completely attenuated the fibrillation of A1-42 
and α1-antitrypsin-derived C-terminal peptides.
95 There are no published data to 
show whether haptoglobin has similar anti-amyloidogenic properties in vitro. 
 
Recent studies exploring the interactions between clusterin and amyloid forming 
proteins revealed that clusterin did not bind to the native form of the substrates tested, 
nor did it interact with mature fibrils.28; 94 Clusterin most potently inhibited amyloid 
formation when it was present during the early stages of fibrillogenesis. Yet, based on 
results obtained by mass spectrometry, the presence of clusterin did not eliminate the 
appearance of a partially unfolded monomeric intermediate identified as the initial 
step in the pathway of lysozyme amyloidosis.94 The addition of clusterin during the 
elongation phase did not greatly alter the kinetics of aggregation of I56T lysozyme.94 
Similarly, clusterin was more effective at suppressing fibril formation in solutions of 
A and SH3 which had been seeded with samples taken from corresponding 
aggregation mixtures during the lag phase compared with those taken from the late 
(plateau) phase.28 This is consistent with data showing that at the same molar 
clusterin:substrate ratio, as the concentration of amyloid forming protein was 
increased, clusterin was less able to inhibit the formation of amyloid by Apo C-II, 
PI3-SH3 and A. Increasing concentrations of amyloid forming protein increase the 
abundance of destabilised monomer, favouring self-association into oligomers able to 
nucleate the aggregation process and thereby shortening the lag phase.28; 93 Taken 
together, the above results suggest that clusterin primarily exerts its effects on 
amyloid formation by binding to destabilized pre-fibrillar oligomeric species present 
at or near the nucleation phase. When in equilibrium with the native fold, destabilised 
and non-native structures can initiate aggregation when present at an abundance as 
low as 1%.96; 97 Therefore, such species are present at concentrations low enough to 
account for the potent sub-stoichiometric effects of the ECs. The binding of ECs such 
as clusterin probably reduces the availability of these species to participate in the 
nucleation events that normally precede fibril formation (Fig. 2). 
 
Despite many reports of the ability of ECs to inhibit fibril formation in vitro, there are 
indications to suggest that they may, at least under certain conditions, actually 
promote the formation or maintain the persistence of amyloid fibrils. 2M binds to 
and protects prion protein from degradation by proteinase K; this protection was not 
exerted by 2M binding to and inhibiting proteinase K.53 In addition, another study 
showed that 2M prevents the trypsin-mediated degradation of fibrils composed of 
either immunoglobulin lambda () light chains or 2M.98 Similarly, the calcium-
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dependent binding of SAP to amyloid fibrils formed from A, serum amyloid A 
protein or immunoglobulin light chain, protected the fibrils from subsequent protease-
mediated degradation.88 This in turn led to suggestions that SAP may promote the 
persistence of amyloid deposits in vivo. For some protein substrates, at low 
clusterin:substrate ratios (1:50-1:500), clusterin promoted the formation of aggregates 
with an increased level of thioflavin T fluorescence, suggesting that (at these ratios) it 
promoted the formation of fibrils from calcitonin, -synuclein and A. At these low 
levels, clusterin was found incorporated into insoluble A and SH3 fibrils.28 Similarly, 
at low SAP:A ratios, SAP promoted the formation of Aβ aggregates;99 at SAP:A 
of 1:1000, short fibrillar-like structures lacking typical amyloid features were formed 
which often contained associated SAP molecules.95 In addition, 2M has been shown 
to stabilize a conformation of the prion protein resistant to proteinase K (PrPRes) that 
is thought to initiate aggregation and is associated with prion disease pathology.53 
Taken together, these results suggest that when ECs are present at low levels relative 
to the substrate they may act to stabilize an otherwise unstable conformation and 
facilitate amyloid fibril formation (Fig. 2). 
 
4.2 The in vitro effects of ECs on amyloid toxicity 
Recent studies have indicated that the location of amyloid deposits in vivo do not 
correlate well with sites of neurotoxicity (e.g. in AD100, amyotrophic lateral sclerosis 
(ALS)101, PD102 and familial amyloidotic polyneuropathy103). Neuronal losses 
associated with these disorders may be brought about by toxicity exerted by smaller 
soluble aggregates (sometimes referred to as oligomers or protofibrils).3 These 
protofibrils have been shown to be more toxic than both the protein/peptide from 
which they are made and mature fibrils constructed from them.11 If this scenario is 
correct, then it follows that at least under some conditions EC-mediated inhibition of 
protein aggregation could actually promote cytotoxicity. When tested against 
neuronal cell lines, under certain specific conditions, clusterin and 2M were shown 
to promote the neurotoxicity of A (clusterin - PC12 cells;104 2M - LAN5 cells57). In 
stark contrast, using primary rat mixed neuronal cultures, others have demonstrated 
that clusterin and 2M can protect cells from A toxicity.61; 105 Even within individual 
studies, depending on the conditions used, clusterin was shown both to protect cells 
and to promote cytotoxicity. Complexes of clusterin and A formed at high ratios of 
clusterin:A (e.g. 1:10) were less toxic to SH-SY5Y cells than A alone; in contrast, 
complexes formed at low ratios of clusterin:A (e.g. 1:500) were more toxic than A 
alone.28 Thus, the effects of ECs, and in particular clusterin, on the toxicity of 
aggregates are complex and have been shown to depend upon the clusterin:substrate 
ratio, the stage of amyloid formation at which the aggregates are formed, and the cell 
type. 
 
It has been postulated that the level of hydrophobicity exposed by aggregates may 
determine their toxicity.3 How this directly relates to the mechanism of their toxicity 
is uncertain and is currently a hotly researched topic, but it is probably due to 
interactions of hydrophobic residues with membranes or other molecules essential for 
normal cellular function.3 This, in part, may explain the differential effects of 
clusterin on toxicity.  When the substrate protein is present at a high molar excess, 
clusterin may be unable to mask all regions of exposed hydrophobicity but instead 
may stabilize aggregates which retain sufficient exposed hydrophobicity to exert 
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toxicity. In contrast, at higher but still sub-stoichiometric ratios of clusterin:A, 
toxicity is reduced.28  
 
Another potentially important factor to consider when trying to understand the in vivo 
effects of ECs on amyloid toxicity, is that in addition to their effects on the nature and 
size of protein aggregates, ECs may also be involved in the physical clearance of 
protein aggregates. This is illustrated by the demonstration that in the presence of 
2M (but not otherwise), SH-SY5Y cells expressing the 2M receptor (LRP) are more 
resistant to Atoxicity than cells that do not.57 The protective effect of 2M could be 
inhibited by RAP (a pan-specific inhibitor of LRP ligand binding). Furthermore, 2M 
promoted A toxicity against LRP-negative LAN5 cells but had the opposite effect 
with LRP-expressing LAN5 transfectants.57 Therefore, although ECs may provide 
cells with some protection by binding to exposed hydrophobic regions on protein 
aggregates, a further protective mechanism may only come into play when 
appropriate cell surface receptors are available to mediate uptake and degradation of 
EC-substrate protein complexes.  
 
4.3 ECs and disposal of extracellular misfolded proteins 
It has been proposed that ECs are scavengers for misfolded proteins in the 
extracellular space, inhibiting protein aggregation and deposition and guiding the 
"damaged" protein substrates to specific receptors for their internalization and 
subsequent lysosomal degradation30 (Fig. 3). This system of EC directed receptor-
mediated endocytosis may play a major role in the maintenance of protein solubility 
in extracellular fluids, including in the brain (interstitial fluid and CSF). Evidence 
supporting this model includes: 
(1) In the CNS, ECs are produced locally in astrocytes and some neuron 
populations106; 107; 108 and can be transported from plasma across the blood brain 
barrier (BBB).109 The receptors LRP and megalin are expressed on the surface of cells 
in contact with CSF (i.e. chloroid plexus and ependymal cells110 and at the BBB109; 111 
and LRP is also found on the surface of astrocytes112 and microglial cells.113  
(2) Clusterin and 2M are both found complexed with soluble amyloid-forming 
proteins in human CSF.53; 114  
(3) It has previously been shown that clusterin-A complexes bind to megalin on the 
surface of mouse teratocarcinoma F9 cells, and are subsequently internalised, 
transported to lysosomes and degraded.31 Similarly, 2M-A complexes are 
internalized via LRP expressed on U87 cells and are subsequently degraded.52  
(4) The normally rapid removal of radiolabelled A from mouse brain is significantly 
inhibited by the LDL family inhibitor RAP and antibodies against LRP-1 and 2M.115 
Furthermore, when complexed with clusterin, the rate of clearance of A from the 
mouse brain across the BBB into plasma is increased by more than 80% and this 
transport is significantly inhibited by anti-megalin antibodies.116  
 
4.4 When quality control is compromised? 
If a system of extracellular protein quality control (QC) operates and is efficient, why 
do protein deposits sometimes develop? Protein aggregation is generally age-related, 
and some proteins such as A accumulate as a part of normal aging.117 In young, 
healthy humans the disposal of proteins such as transthyretin or peptides like A 
appears to be efficient, since there are no apparent protein deposits. Thus, it is likely 
that protein deposition may represent an age-dependent overloading of the QC system 
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that ultimately results in toxicity and neurodegeneration. If the extracellular QC 
system is overloaded in protein folding-related diseases, it is critical to pinpoint the 
factors and pathways involved to facilitate identification of new potential therapeutic 
strategies.  
 
One poorly understood pathway relates to the observation that under some conditions 
ECs can actually promote the formation of amyloid fibrils; clusterin, 2M and SAP 
have been shown to promote fibril formation in vitro28; 53; 99; 118 (see section 4.1). In 
addition, in a transgenic mouse model expressing amyloid precursor protein (APP; 
PDAPP mice), a comparison of clusterin -/- and clusterin +/+ mice showed no 
difference in the amount of A deposited in the brain, however the amount of 
thioflavin S positive material was larger in clusterin +/+ mice.119 Although there was 
no electron microscopy data to confirm that this was in fact amyloid fibrils, the 
authors suggest that this demonstrates clusterin promoted fibril formation in this 
model. In contrast, PDAPP apoE−/−, clusterin−/− mice had significantly increased 
A levels in CSF and intersititial fluid and thioflavin–S  deposits in the brain.120 The 
results of this latter study were interpreted as suggesting that clusterin works 
cooperatively with ApoE to inhibit the formation of A amyloid in the brain. The 
interpretations presented from these two studies are seemingly contradictory, and a 
clear understanding of the in vivo role of clusterin in amyloidogenesis has yet to be 
achieved. An important factor influencing the nature of the effect of clusterin on 
amyloid formation, at least in vitro, is the clusterin:substrate protein ratio. At very low 
ratios of clusterin:substrate, clusterin has been shown to enhance amyloid associated 
thioflavin T fluorescence suggesting that it increases amyloid formation, while at 
higher but still sub-stoichiometric ratios have the opposite effect (see section 4.1). A 
similar biphasic effect on amyloid formation has also been shown for the intracellular 
yeast chaperone hsp104.121  
 
It is possible that at times in local microenvironments, the concentrations of ECs are 
low and that under these conditions they actually promote the formation of amyloid 
fibrils (see section 4.1). Interestingly, under conditions of high substrate protein 
excess, clusterin becomes incorporated into insoluble aggregates.28 Sequestration of 
clusterin into deposits would effectively lower its availability, and potentially further 
promote fibril formation. If the other ECs behave similarly, then it is no surprise that 
all are found associated with deposits (see sections 3.1-3.4, and Fig. 2). In humans 
with AD122; 123 and Creutzfeldt Jacob disease122; 124 the levels of clusterin mRNA are 
increased, however, there is no associated increase in clusterin protein levels in AD 
CSF125 and the level of clusterin protein in CSF is decreased by 2.5 fold in Creutzfeldt 
Jacob disease.126 In addition, decreased levels of clusterin in the eye are thought to be 
responsible for deposition of Pseudo exfoliation (PEX) material in PEX syndrome127 
(again clusterin is found associated with PEX deposits).  
 
Another factor that could favour the development of amyloid pathology is a 
dysfunction in the expression or function of relevant cell surface receptors. Under 
some conditions, ECs may stabilize toxic conformations of substrate proteins with 
exposed hydrophobicity (see section 4.2). If receptor-mediated clearance is 
inadequate, the persistence of such toxic complexes could manifest as neuronal 
damage. In vitro assays demonstrated that when neuronal cells were in mixed cultures 
with astrocytes and microglia (which express receptors capable of specifically binding 
to ECs, e.g. LDLR family members), by complexing with A both clusterin and 2M 
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were neuroprotective.  However, when neuronal cells were cultured alone, complexes 
of clusterin or 2M with A were neurotoxic, suggesting that complexes of EC and 
aggregating protein may be toxic in the absence of receptor mediated endocytosis 
pathways. Moreover, there are increased plasma concentrations of several LRP 
ligands in AD patients, including ApoE, 1 anti-chymotrypsin and urokinase128; 129; 
130 suggesting that LRP may be either overwhelmed, downregulated or faulty in AD. 
More recently, this has been confirmed by data showing that LRP expression at the 
BBB is decreased in AD patients and mouse models.131 As discussed above (see 
section 4.3), this is consistent with the results from mouse models where antibody-
mediated blockade of megalin and LRP significantly prolonged the time taken to clear 
A from the brain.115; 116  
 
5.0 CONCLUSION & FUTURE DIRECTIONS 
 
In recent years our understanding of the nature and significance of amyloid formation  
and deposition and the role that these play in disease has taken dramatic leaps forward. 
Further advances in understanding of the mechanisms which control extracellular 
protein folding are likely to identify new strategies for effective disease therapies. 
This review focused on what little is known about quality control of the folding of 
amyloid forming proteins in extracellular spaces. Since the EC field is still in its 
infancy, this review is necessarily speculative in a number of areas. However, it is 
quite clear that amyloid forming proteins such as A and prion proteins are 
‘chaperoned’ by what have become termed extracellular chaperones. It is proposed 
that once bound to misfolded proteins, ECs guide them to specific receptors that 
function to direct proteins into lysosomes for degradation. In this scenario, specific 
receptors such as LRP and megalin are an integral and critical part of a quality control 
system which provides protection against dangerously hydrophobic proteins/peptides. 
Since relatively little is known about ECs and their role in protein deposition diseases 
many future research directions are possible. Initially, it will be important to better 
understand the mechanism by which, under some conditions, ECs promote amyloid 
formation, as this has clear relevance to the development of any EC-based therapies. 
Certainly, it will be critical to evaluate the roles of ECs in a variety of in vivo models 
of protein deposition diseases. It may be possible to accelerate the pace of advances 
by utilizing innovative new disease models such as those developed using the fruit fly 
Drosophila. The short generation times and ease of genetic manipulation in these 
models create opportunities not accessible with mammalian systems. Much remains to 
be discovered, ensuring that exciting times lie ahead. 
 
 
 
FIGURE LEGENDS 
 
Figure 1. A schematic representation of the amyloid forming pathway. The 
formation of amyloid fibrils occurs via a nucleation dependent mechanism in which 
soluble prefibrillar oligomers or nuclei are formed during the lag phase. These 
oligomeric species then act as templates to sequester other aggregation-prone 
intermediates, leading to rapid fibril growth (represented by the exponential 
elongation phase) and subsequently, to the formation of insoluble mature amyloid 
fibrils. The plateau phase represents the steady state when maximum fibril growth has 
been reached. Adapted from 3. 
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Figure 2. The biphasic effects of chaperones on amyloid fibril formation. The 
kinetics of the amyloid assembly process is often depicted as a sigmoidal curve to 
reflect the three distinct phases characterizing the fibril formation pathway (i.e. lag, 
elongation and plateau; see also Figure 1). Complete inhibition of fibril formation can 
be achieved when clusterin and 2M are present at high (but usually still sub-
stoichiometric) levels relative to the substrate protein. Yet, at low EC:substrate ratios, 
extensive amyloid or amyloid-like fibril formation is observed for some substrate 
proteins, suggesting that in these cases, ECs may be stabilizing an otherwise unstable 
conformation and promoting amyloid fibril formation. Figure reproduced with kind 
permission of xxxxx. (permission requested, outcome to be advised) 
 
 
Figure 3. Receptor-mediated endocytosis and lysosomal degradation – a putative 
quality control mechanism for extracellular protein folding. An extracellular 
quality control process was recently proposed in which extracellular chaperones (EC) 
facilitate the clearance of non-native protein structures via receptor-mediated 
endocytosis and intracellular, lysosomal degradation. The existence of such a quality 
control mechanism would ensure that proteins do not persist beyond their intended 
lifespan in the extracellular space and normally counteract the development of protein 
aggregation disease pathologies.  
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